AcelRx Pharmaceuticals, Inc. today announced that the Company and its investigators will be presenting a subgroup analysis of the Phase 3 SAP301 study results by surgery type. The analysis will be presented at the Society for Ambulatory Anesthesia 31 st Annual Meeting, which is being held May 5-7, 2016 in Orlando, FL.. About AcelRx Pharmaceutical
Amphastar Pharmaceuticals, Inc. announced today that Jason Shandell, President will be presenting at the Bank of America Merrill Lynch 19 th Annual Health Care Conference on Thursday, May 12, 2016 at 9:20 a.m. Pacific Standard Time in Las Vegas, NV.. Amphastar s long-standing relationship with the major group purchasing organizations and drug
Connecticut's General Fund is getting an injection of nearly $5 million thanks to a settlement with a pharmaceutical company involving the Medicaid program. State Attorney General George Jepsen, Chief State's Attorney Kevin Kane, and Department of Social Services Commissioner Roderick Bremby announced the settlement. The program requires drugmakers
At the 2016 Haematogenic Immunity Summit held in Hangzhou from April 22 to 24, 2016, Professor Huang He from the First Affiliated Hospital of Zhejiang University presented on the results for ten clinical cases that used CAR-T cell therapy for the treatment of leukemia. The trial, jointly conducted by the hospital and the company Innovative Cellul
Daiichi Sankyo Co. said Friday an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the Japanese drugmaker around 56.2 billion yen for concealing critical information about the firm. Daiichi Sankyo sold its stake in Ranbaxy Laboratories Ltd. to India's Sun Pharmaceutical Industries Ltd. las
Investing.com Shares in Endo International PLC plummeted nearly 25% in after-hours trading, after the specialty pharmaceutical maker slashed its full-year outlook and a top executive announced his departure from the company on Thursday. In addition, Endo announced on Thursday that Brian Lortie, U.S. Branded Pharmaceuticals, has decided to step do
By a News Reporter-Staff News Editor at Drug Week Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, announced preclinical data for the discovery and early development of two potential drug candidates, an immune checkpoint inhibitor targeting adenosine and a novel antibody-drug conjugate...
That would essentially ban 99 percent of all vapor products currently on the market pending FDA approval. The following statements from vaping and smoking-cessation experts at The Heartland Institute a free-market think tank may be used for attribution. If the new FDA rule opens the door to continued legal marketing of tobacco harm-reduction
By a News Reporter-Staff News Editor at Drug Week AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced the appointment of Joseph Horrigan as chief medical officer. Dr. Horrigan comes to AMO Pharma with more than two decades of experience in the pharmaceuti
In this report, all references to "we," "our," "us," "La Jolla" and the "Company" refer to La Jolla Pharmaceutical Company, a California corporation, and its subsidiaries. The forward-looking statements in this report involve significant risks, assumptions and uncertainties, and a number of factors, both foreseen and unforeseen, which could cause a
HEIDELBERG, Germany Novaliq GmbH, a pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced today the completion of enrollment in its Phase 2 clinical trial that is evaluating the safety, efficacy and tolerability of CyclASol for the treatme
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors MOECK, Greg; MATKOVITS, Theresa; BILLSTEIN, Stephan A.; EAGLE, Gina; PATEL, Ketna; ARHIN, Francis F., filed on April 15, 2014, was made available online on April 21, 2016. Th
By a News Reporter-Staff News Editor at Drug Week A patent by the inventors Appling, William M.; Engelhard, Stephen N.; Barton, Matthew G., filed on December 30, 2012, was published online on April 19, 2016, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 9314561 is assigned to Delcath Sy
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Johnson, B. Ron; McCarthy, James P., filed on August 22, 2014, was published online on April 19, 2016. The assignee for this patent, patent number 9314526, is QUADEX PHARMACEUTICALS,
By a News Reporter-Staff News Editor at Drug Week A patent by the inventor Cain, Katharine Lacy, filed on July 29, 2014, was published online on April 19, 2016, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 9315565 is assigned to UCB Pharma, S.A.. The following quote was obtained by the
By a News Reporter-Staff News Editor at Drug Week Allergan, Inc. has been issued patent number 9314425, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventor is Whitcup, Scott M.. This patent was filed on January 16, 2015 and was published online on April 19, 2016.
By a News Reporter-Staff News Editor at Drug Week REGENERON PHARMACEUTICALS, INC. has been issued patent number 9315281, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventor is Dissanayake, Tikiri Jean. This patent was filed on November 19, 2012 and was published online on April 19, 2016.
By a News Reporter-Staff News Editor at Drug Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventor Maier, Hans Jurgen, filed on October 9, 2012, was published online on April 19, 2016. The patent's assignee for patent number 9314441 is R.P. Scherer Technologies, LLC. News editors obtained the following quote from
An Internet- based literature search through April 2015 was performed for information related to biosimilars in chronic inflammatory disorders. " The news correspondents obtained a quote from the research from the University of Nevada, "Keywords were as follows: biosimilar, development, manufacturing, characterization, structural, functional, precl
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today presentations of clinical data for apaziquone to be presented at an oral presentation and a moderated poster session at the American Urological Association Education and.
By a News Reporter-Staff News Editor at Drug Week Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for oncology and hematologic diseases, announced the presentation of positive preclinical data on TP-0903, an AXL kinase inhibitor. The data were presented in a poster entitled "AXL inhibition leads to a reversal of a mes
TOLMAR Pharmaceuticals, Inc., today announced that approval has been received from FDA for a label update for ELIGARD , indicated for the palliative treatment of advanced prostate cancer. "The results of our stability studies and subsequent FDA approval of the label update provides practices greater flexibility for storage and administration o
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "SHARED SOLUTIONS" by Herschel Perel, representing Teva Pharmaceuticals USA. The owner/registrar information for this application is: Herschel Perel, Teva Pharmaceuticals
By a News Reporter-Staff News Editor at Drug Week Sunny Pharmtech Inc., a Taiwan- based API and finished-dose drug development company, and Vitruvias Therapeutics LLC, a generic drug development company, announced that they have signed two additional agreements to co-develop and market two additional high-value generic drugs. This will expand the
By a News Reporter-Staff News Editor at Drug Week Yabao Pharmaceutical Co, Inc. and Salus Pharma LLC announced a strategic partnership to co-develop, manufacture and commercialize high technological barrier generic drugs worldwide. Peng Wang, President of R&D and Head of International Business, Yabao Pharmaceutical Co. "This partnership further..